GLP1RA medications include the short-acting types lixisenatide ... or an angiotensin receptor blocker (ARB). beta blockers, and calcium channel blockers among others. Dyslipidemia (high ...

WASHINGTON -- Across the different classes of heart failure (HF) drugs, beta-blockers stood out for their association with limb loss in patients with concomitant chronic limb-threatening ischemia ...

It has been assumed that β-AR antagonists (β-blockers) have a direct favorable influence on the heart, but our results challenge this view, suggesting that β-blockers may also act directly in ...

However, β blockers do not all share the same clinical outcomes with respect to efficacy or safety in many of these conditions. This is especially true in HF, where differences in reverse ...

WILMINGTON, Del., May 02, 2025--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

and long-acting beta2-agonist (LABA) maintenance treatments, AZ said. Data from the KALOS and LOGOS studies will be shared with regulatory authorities and presented at an upcoming medical meeting ...

a long-acting beta2-adrenergic agonist (LABA). The replicate, randomized, double-blind, confirmatory KALOS (ClinicalTrials.gov Identifier: NCT04609878) and LOGOS (ClinicalTrials.gov Identifier ...

(Alliance News) - AstraZeneca PLC on Friday reported that its triple-combination asthma treatment Breztri Aerosphere met all primary endpoints in two late-stage clinical trials, raising the ...